Eric J. Sherman, MD, on Agents for Treating RET Fusion–Positive Thyroid Cancer

Video

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Eric J. Sherman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, who spotlighted agents that are currently used for the treatment of RET fusion–positive thyroid cancer. Although only a subset of patients with papillary thyroid cancer have disease that is driven by RET fusions, over half of all patients with medullary disease have RET mutations. Due to this, RET is believed to play an important role in the treatment of thyroid cancer

Transcript:

One of the things that we knew about for a long time is that a subset of thyroid cancers are driven by RET fusion genes [in papillary disease]. For medullary [disease], on other hand, probably about 55% or 60% are driven by RET mutations, either hereditary or somatic. We know RET plays a very important role in the treatment of thyroid cancers. A lot of the treatments that started out for medullary thyroid cancer were really based on the fact that certain drugs like cabozantinib [Cabometyx] and vandetanib [Caprelsa] targeted RET. Because of that, although these drugs hit many different targets, pretty good activity was seen and both vandetanib and cabozantinib got FDA approvals. [However], other drugs like sunitinib [Sutent], pazopanib [Votrient], and lenvatinib [Lenvima] were also shown to have reasonable activity, although they never went through randomized phase 3 studies.

Reference

Sherman EJ, Wirth LJ, Shah MH, et al. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: a clinical trial update. J Clin Oncol. 2021;39(suppl 15):6073. doi:10.1200/JCO.2021.39.15_suppl.6073

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Related Content